Altered network efficiency in isolated REM sleep behavior disorder: A multicentric study
- PMID: 40791089
- PMCID: PMC12340432
- DOI: 10.1002/alz.70574
Altered network efficiency in isolated REM sleep behavior disorder: A multicentric study
Abstract
Introduction: Isolated rapid eye movement (REM) sleep behavior disorder (iRBD), characterized by abnormal movements during REM sleep, is a prodromal stage of dementia with Lewy bodies (DLB) and Parkinson's disease (PD). While iRBD shows emerging brain changes, their impact on structural connectivity and network efficiency, and their predictive value, remain poorly characterized.
Methods: In this international prospective study, 198 polysomnography-confirmed iRBD patients and 174 controls underwent diffusion magnetic resonance imaging and were analyzed. Cutting-edge diffusion tractography and network-based statistics were applied to reconstruct individual connectomes and assess network properties predicting DLB or PD.
Results: Structural architecture was already disrupted in iRBD, with both reduced and compensatory increased connections. Global efficiency was decreased. Local efficiency in motor regions was altered and associated with early clinical symptoms. Altered local efficiency in the supramarginal gyrus predicted DLB only.
Discussion: Early disruption of brain architecture in iRBD predicts progression to synucleinopathy-related dementia, offering a novel potential prognostic biomarker.
Highlights: Isolated rapid eye movement sleep behavior disorder (iRBD) patients show significant alterations in inter-regional structural connectivity. Global efficiency is reduced in iRBD compared to controls. Areas with increased local efficiency contribute to decreased global efficiency. Altered network efficiency is associated with emerging Parkinsonian features. Higher supramarginal efficiency predicts dementia with Lewy bodies in iRBD.
Keywords: dementia with Lewy bodies; diffusion magnetic resonance imaging; graph theory; parasomnias; sleep; structural connectivity; synucleinopathies.
© 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Conflict of interest statement
The authors declare no conflicts of interest. Author disclosures are available in the supporting information.
Figures
References
Publication types
MeSH terms
Grants and funding
- Fonds de recherche du Québec - Santé, the Canadian Institutes of Health Research, the W. Garfield Weston Foundation, the Michael J. Fox Foundation for Parkinson's Research, and the National Institutes of Health
- Canada Research Chair in Cognitive Decline in Pathological Aging
- CIHR, Michael J. Fox Foundation, NIH, Roche Diagnostics, and the Weston Foundation
- NU21-04-00535/Czech Health Research Council
- LX22NPO5107/National Institute for Neurological Research
- European Union - Next Generation EU
- National Institute for Health and Care Research (NIHR) Oxford Health Clinical Research Facility and the NIHR Oxford Biomedical Research Centre
- IHU (IAIHU-06)/the Paris Institute of Neurosciences
- ANR-11-INBS-0006/Agence Nationale de la Recherche
- Control-PD (JPND Cognitive Propagation in Prodromal Parkinson's Disease)
- Parkinson's UK, the Oxford Biomedical Research Centre, CPT, EPND, and the Michael J. Fox Foundation
- Michael J. Fox Foundation
- 4D Pharma, AbbVie Inc., AcureX Therapeutics, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's (ASAP), Avid Radiopharmaceuticals, Bial Biotech, Biogen, BioLegend, Bristol Myers Squibb, Calico Life Sciences LLC, Celgene Corporation, DaCapo Brainscience, Denali Therapeutics, The Edmond J. Safra Foundation, Eli Lilly and Company, GE Healthcare, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen Pharmaceuticals, Lundbeck, Merck & Co., Inc., Meso Scale Diagnostics, LLC, Neurocrine Biosciences, Pfizer Inc., Piramal Imaging, Prevail Therapeutics, F. Hoffmann-La Roche Ltd
- Genentech Inc., Sanofi Genzyme, Servier, Takeda Pharmaceutical Company, Teva Neuroscience, Inc., UCB, Vanqua Bio, Verily Life Sciences, Voyager Therapeutics, Inc., and Yumanity Therapeutics, Inc
- 0000000082/Alzheimer Society Canada
- 2023-0000000122/Parkinson Canada
- J-2101/PUK_/Parkinson's UK/United Kingdom
- National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)
- NIHR Oxford Health Clinical Research Facility
- NIHR Oxford Biomedical Research Centre (BRC)
- Department of Health and Social Care
- Financed by European Union - Next Generation EU
- ANR-10-IAIHU-06/Programme d'investissements d'avenir
- ANR-10-IAIHU-06/Programme d'investissements d'avenir
- IAIHU-06/Paris Institute of Neurosciences - IHU
- Électricité de France (Fondation d'Entreprise EDF)
- Control-PD (Joint Programme-Neurodegenerative Disease Research [JPND] Cognitive Propagation in Prodromal Parkinson's disease)
- Fondation Thérèse et René Planiol
- Fonds Saint-Michel
- Parkinson's disease from Energipole (M. Mallart)
- Société Française de Médecine Esthétique (M. Legrand)
- Institut de France to Isabelle Arnulf (for the ALICE Study)
- Canadian Institutes of Health Research (CIHR)
- Fonds de recherche du Québec - Santé (FRQ-S)
- W. Garfield Weston Foundation
- PPG-2023-0000000122/Parkinson Society Canada
LinkOut - more resources
Full Text Sources
Medical
